Vall d'Hebron Instituto de Oncologia

Barcelona, Barcelona 08035

1 studies enrolling now · 1 studies all time

What they study most

Advanced Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer, PIK3CA Mutation, Solid Tumor, Adult, Unresectable Solid Tumor

Studies at this site

• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer — Recruiting now